GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Rhea-AI Summary

GRI Bio (NASDAQ: GRI), a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic and autoimmune diseases, announced its participation in the upcoming Webull Financial Corporate Connect Webinar Series: Biotech/MedTech.

The virtual presentation will be delivered by CEO Marc Hertz, PhD on Wednesday, August 20, 2025 at 2:20 PM ET. The event is part of a broader virtual conference taking place from August 19-21, 2025.

Live video webcast on Wednesday, August 20^th at 2:20 PM ET

LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech being held virtually August 19-21, 2025.

Details for the presentation are as follows:

Date and Time: Wednesday, August 20, 2025 at 2:20 PM ET
Presenter: Marc Hertz, PhD, President, Chief Executive Officer and Director
Registration Link: HERE

About Webull Financial 

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC ("Webull Financial"), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

About GRI Bio, Inc.

GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.

Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com

FAQ

When is GRI Bio (NASDAQ: GRI) presenting at the Webull Financial Corporate Connect Webinar Series?

GRI Bio will present on Wednesday, August 20, 2025 at 2:20 PM ET.

Who will be presenting for GRI Bio at the Webull Financial Webinar?

Marc Hertz, PhD, who serves as President, Chief Executive Officer and Director of GRI Bio, will be presenting.

What is GRI Bio's main focus as a biotechnology company?

GRI Bio focuses on developing Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases.

What is the format of the Webull Financial Corporate Connect Biotech/MedTech event?

The event is being held virtually from August 19-21, 2025.